In 829 AHSCT patients, 21% experienced major adverse cardiovascular events after a median 4 years; predictors included age, hypertension, history of VTE, HF, CTRCD, anthracycline exposure, and high-ri
What are the predictors of late major adverse cardiovascular events (>100 days) in patients undergoing allogeneic hematopoietic stem cell transplantation?
Age, cardiovascular risk factors, and specific oncologic history independently predict late major adverse cardiovascular events in allogeneic hematopoietic stem cell transplant recipients.
Abstract Background Although patients undergoing allogeneic hematopoietic stem cell transplantation (AHSCT) have a higher risk of late cardiovascular complications, comprehensive data on these risks within large cohorts remain limited. Purpose To identify predictors of late cardiovascular events (100 days) in a large cohort of AHSCT patients. Methods We conducted a retrospective monocentric study including all consecutive patients aged 15 years and older with hematologic malignancies who underwent AHSCT between 2011 and 2020. Data were extracted from electronic medical records, including demographic, clinical, and transplant-specific variables. The primary composite outcome was major adverse cardiovascular events (MACE), including cardiovascular death, heart failure (HF), rhythm/conduction disorders, acute arterial events, venous thromboembolism (VTE), and myopericarditis. Predictors of MACE were analyzed using Cox proportional hazards regression and Fine-and-Gray models. Results Among 829 patients recruited (age 44±16 years, 62% male) at 100th days after allograft, 21% experienced MACE after a median (interquartile range, IQR) follow-up of 4 (1-7) years. The median time to the first event was 18 months, with a median (IQR) age at the first event of 53 (44-59) years. After adjustment, independent predictors for late MACE (100 days), independent predictors were: age, hypertension, history of VTE, supraventricular tachycardia, history of HF, CTRCD, previous liposomal anthracycline exposure, and high-risk Sorror category. Conclusion Our study identifies independent predictors of late MACE, including demographic data, cardiovascular risk factors, history of cardiovascular disease and oncologic history.Description of late MACE Adjusted survival curves for late MACE
Sibilia et al. (2025) studied this question. In 829 AHSCT patients, 21% experienced major adverse cardiovascular events after a median 4 years; predictors included age, hypertension, history of VTE, HF, CTRCD, anthracycline exposure, and high-ri.